Siminder Atwal - Concepedia

Author

Siminder Atwal

The University of Texas MD Anderson Cancer Center

Also Known As

S. Atwal, S. K. Atwal, Siminder Atwal, Siminder K. Atwal, Siminder Kaur Atwal

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Peter MacCallum Cancer Centre The University of Melbourne St Vincent's Hospital Melbourne The University of Sydney

About

Siminder Atwal is an author at The University of Texas MD Anderson Cancer Center specializing in cancer research, medicine, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	70
2	Cell Biology	2	2	42
3	Engineering	1	1	12
4	Health Sciences	1	1	28
5	Cellular Therapies	1	1	30

Siminder Atwal

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib Elizabeth A. Punnoose, Siminder Atwal, Weiqun Liu, Clinical Cancer Research	2012	417
Molecular Biomarker Analyses Using Circulating Tumor Cells Elizabeth A. Punnoose, Siminder Atwal, Jill M. Spoerke, PLoS ONE	2010	294
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up Judith Trotman, Stephen Opat, David Gottlieb, Blood	2020	105
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma Constantine S. Tam, Stephen Opat, David Simpson, Blood Advances	2021	96
Safety and Efficacy of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma Veronika Bachanová, Armin Ghobadi, Krish Patel, Blood	2021	77
A Head-To-Head Phase III Study Comparing Zanubrutinib Versus Ibrutinib in Patients with Waldenström Macroglobulinemia Constantine S. Tam, Véronique Leblond, William Novotny, Future Oncology	2018	38
Preliminary results of a phase I trial of FT516, an off-the-shelf natural killer (NK) cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line expressing high-affinity, non-cleavable CD16 (hnCD16), in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL). Paolo Strati, Veronika Bachanová, Aaron M. Goodman, Journal of Clinical Oncology Cell TherapyImmunologyPharmacotherapyImmunotherapeuticsOff-the-shelf Natural Killer	2021	30
UPDATED SAFETY AND EFFICACY DATA IN THE PHASE 1 TRIAL OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) TREATED WITH BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB‐3111) Constantine S. Tam, M. Wang, David Simpson, Hematological Oncology PathologyPharmacotherapyPre-clinical PharmacologyHematological MalignancyNeuro-oncology	2019	28
Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial Gavin Cull, David Simpson, Stephen Opat, Blood	2019	21
Phase I Study of FT516, an Off-the-Shelf iPSC-Derived NK Cell Therapy, in Combination with Rituximab in Patients with Relapsed/Refractory B-Cell Lymphoma Krish Patel, Veronika Bachanová, Aaron M. Goodman, Blood	2021	17

Page 1